Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC
Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap sarotalocan for the treatment of non-muscle invasive bladder cancer (NMIBC). According to the NASDAQ-listed clinical-stage biotech company, the early-stage multi-center, open label study is likely to take in nearly 23 […]